Results 151 to 160 of about 33,100 (295)

Do preclinical seizure models predict success or failure in anti‐seizure drug development? A retrospective analysis of 89 compounds with divergent clinical outcomes for epilepsy

Epilepsia, EarlyView.
Abstract Anti‐seizure medication (ASM) discovery remains a major challenge despite over 30 commercially available options. One persistent obstacle for any promising candidate compound to successfully move from preclinical study to clinical approval has been the ambiguity in preclinical model selection.
Wolfgang Löscher, Melissa Barker‐Haliski   +1 more
wiley   +1 more source

Effect of Alkyl Chain Length on Physicochemical and Pharmacokinetic Performance of Aripiprazole Fatty Acid Prodrugs for Long-Acting Injectable Suspensions. [PDF]

Pharmaceutics
Chen A, Lai C, Zhai H, Zhang S, Zhang Y, Cai T.   +5 more
europepmc   +1 more source

Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Proton pump inhibitors (PPIs) are commonly prescribed in patients with cancer. Prior studies suggest concomitant PPI use may reduce the efficacy of oral capecitabine through impaired absorption, with no interaction expected with intravenous 5‐fluorouracil (5‐FU). Using the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD),
Matthew Loft, Vinoja Ganeshanathan, Rachel Wong, Shehara Mendis, Matthew Croxford, Ian T. Jones, Grace Gard, Sue‐Anne McLachlan, Jeanne Tie, Lucy Gately, Peter Gibbs   +10 more
wiley   +1 more source

Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis-Mediated Positive Feedback Loop. [PDF]

Adv Sci (Weinh)
Feng W, Yang R, Weng C, Li C, Shi W, Chen Y, Yang Y, Liu Y, Ge P, Zhang H.   +9 more
europepmc   +1 more source

Cysteine Peptidases in Antitumor Immunity: Unraveling Antigen‐Presenting Cell Regulation and Therapeutic Potential

iMetaMed, EarlyView.
This review systematically summarizes the central role of cysteine peptidases in modulating antigen‐presenting cell (APC) function and antitumor immune responses, highlighting their critical significance in overcoming tumor immune evasion. Current research has established that cysteine peptidase subtypes, including cathepsins B, S, L, and X, exert ...
Yimao Wu, Xiaoyan Chen, Zichang Chen, Yalun Liang, Gokhan Zengin, Qian Zhang, Wenlong Sun, Meng‐Yao Li   +7 more
wiley   +1 more source

PBPK Modeling of CES1-Activated Prodrugs Across Different Age Groups: Simultaneous Prodrug-Metabolite Prediction for Oseltamivir, Enalapril, and Cilazapril. [PDF]

Pharmaceutics
Li P, Yang Y, Jiang L, Wang J.
europepmc   +1 more source

[Glucuronyl paclitaxel (Taxol) derivatives as tumor activated prodrugs].

, 2005
International audienceThree glucuronyl prodrugs of paclitaxel have been synthesized in order to be activated by the B-glucuronidase present within the necrotic areas of tumors.
Schmidt, Frédéric
core  

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source

Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs. [PDF]

Angew Chem Int Ed Engl
Wang AX, Liu B, Ackerman EM, Xiang Y, Nguyen HV, Jiang Y, Koehler AN, Johnson JA.   +7 more
europepmc   +1 more source

Research Progress of Berberine in Kidney Disease: Targeting Mitochondria and Ferroptosis

iNew Medicine, EarlyView.
This figure illustrates the model‐specific renoprotective mechanisms of berberine (BBR) across three major kidney diseases. From left to right, the diagram shows that BBR targets distinct core pathways depending on the pathological context: in diabetic nephropathy (DN), BBR activates AMPK to improve mitochondrial energy metabolism; in acute kidney ...
Liuqing Wang, Rongyu Guo, Xiaojun Feng, Liqin Tang   +3 more
wiley   +1 more source